Abstract
Objectives
To investigate the relationship between functional tumour parameters measured during preoperative 18F-FDG PET/CT and clinical outcomes in patients with uterine carcinosarcoma.
Methods
For patients with pathologically proven uterine carcinosarcoma, we determined the maximal and average standardized uptake values, cumulative total lesion glycolysis (TLG) and sum of all metabolic tumour volumes (MTVs). Their predictive value for recurrence and the effects of pretreatment functional tumour activity on patient survival were compared.
Results
Clinicopathological data from 28 eligible patients were reviewed. The median duration of progression-free survival was 18.6 months (range 6.1–84.5 months), and 10 (35.7 %) patients experienced recurrences. Univariate analyses showed significant associations between recurrence and tumour size, lymph node metastasis, high TLG and MTV values, and ovarian invasion. Multivariate analysis identified high TLG value as an independent risk factor for recurrence (p = 0.048, hazard ratio 115.261, 95 % confidence interval 1.041–12,765.483). Kaplan–Meier survival curves showed that progression-free survival significantly differed in groups categorized according to TLG (p = 0.007, log-rank test).
Conclusions
Preoperative TLG measured with 18F-FDG PET/CT was statistically significantly associated with uterine carcinosarcoma recurrence. Metabolic parameters can provide useful quantitative criteria for disease prognostication in patients with uterine carcinosarcoma before treatment.
Key Points
• Preoperative TLG was an independent risk factor for recurrence in uterine carcinosarcoma.
• Progression-free survival significantly differed in groups categorized by TLG.
• Metabolic parameters can provide useful quantitative criteria for disease prognostication.
Similar content being viewed by others
Abbreviations
- CT:
-
Computed tomography
- FIGO:
-
International Federation of Gynaecology and Obstetrics
- 18F-FDG:
-
18F-fluorodeoxyglucose
- LN:
-
Lymph node
- MTV:
-
Metabolic tumour volume
- PET:
-
Positron emission tomography
- PFS:
-
Progression-free survival
- SUV:
-
Standardized uptake value
- TLG:
-
Total lesion glycolysis
References
Harlow BL, Weiss NS, Lofton S (1986) The epidemiology of sarcomas of the uterus. J Natl Cancer Inst 76:399–402
Prat J (2009) FIGO staging for uterine sarcomas. Int J Gynaecol Obstet 104:177–178
Bansal N, Herzog TJ, Seshan VE et al (2008) Uterine carcinosarcomas and grade 3 endometrioid cancers: evidence for distinct tumor behavior. Obstet Gynecol 112:64–70
Bland AE, Stone R, Heuser C et al (2009) A clinical and biological comparison between malignant mixed mullerian tumors and grade 3 endometrioid endometrial carcinomas. Int J Gynecol Cancer 19:261–265
Tong SY, Lee JM, Choi YJ et al (2012) The comparison of clinicopathological characteristics in primary malignant mixed mullerian tumour with epithelial endometrial carcinoma. Aust N Z J Obstet Gynaecol 52:44–48
Amit A, Schink J, Reiss A, Lowenstein L (2011) PET/CT in gynecologic cancer: present applications and future prospects–a clinician's perspective. Obstet Gynecol Clin N Am 38:1–21, vii
Erdi YE, Macapinlac H, Rosenzweig KE et al (2000) Use of PET to monitor the response of lung cancer to radiation treatment. Eur J Nucl Med 27:861–866
Makhija S, Howden N, Edwards R, Kelley J, Townsend DW, Meltzer CC (2002) Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review. Gynecol Oncol 85:53–58
Hubner KF, McDonald TW, Niethammer JG, Smith GT, Gould HR, Buonocore E (1993) Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-[18F]deoxyglucose (2-[18F]FDG). Gynecol Oncol 51:197–204
Francis RJ, Byrne MJ, van der Schaaf AA et al (2007) Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. Nucl Med 48:1449–1458
Veit-Haibach P, Schaefer NG, Steinert HC, Soyka JD, Seifert B, Stahel RA (2010) Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma. Lung Cancer 67:311–317
FIGO Committee on Gynecologic Oncology (2014) FIGO staging for carcinoma of the vulva, cervix, and corpus uteri. Int J Gynaecol Obstet 125:97–98
Metz CE (1978) Basic principles of ROC analysis. Semin Nucl Med 8:283–298
Chung HH, Kim JW, Han KH et al (2011) Prognostic value of metabolic tumor volume measured by FDG-PET/CT in patients with cervical cancer. Gynecol Oncol 120:270–274
Chung HH, Kwon HW, Kang KW et al (2012) Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis in patients with epithelial ovarian cancer. Ann Surg Oncol 19:1966–1972
Chung HH, Lee I, Kim HS et al (2013) Prognostic value of preoperative metabolic tumor volume measured by 18F-FDG PET/CT and MRI in patients with endometrial cancer. Gynecol Oncol 130:446–451
Gulec SA, Suthar RR, Barot TC, Pennington K (2011) The prognostic value of functional tumor volume and total lesion glycolysis in patients with colorectal cancer liver metastases undergoing 90Y selective internal radiation therapy plus chemotherapy. Eur J Nucl Med Mol Imaging 38:1289–1295
Chen HH, Chiu NT, Su WC, Guo HR, Lee BF (2012) Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Radiology 264:559–566
Lim R, Eaton A, Lee NY et al (2012) 18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma. J Nucl Med 53:1506–1513
Acknowledgments
The scientific guarantor of this publication is Gi Jeong Cheon. The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article. This study has received funding by Seoul National University and Seoul National University Hospital. This study was supported by the Research Resettlement Fund for new faculty of Seoul National University, and by grant no. 3420130200 (2013-0362) and grant no. 0320140270 (2014-1040) from the Seoul National University Hospital Research Fund. No complex statistical methods were necessary for this paper. Institutional review board approval was obtained. Written informed consent was waived by the institutional review board.
Methodology: retrospective, diagnostic or prognostic study, multicentre study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lee, JW., Heo, E.J., Moon, S.H. et al. Prognostic value of total lesion glycolysis on preoperative 18F-FDG PET/CT in patients with uterine carcinosarcoma. Eur Radiol 26, 4148–4154 (2016). https://doi.org/10.1007/s00330-016-4264-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-016-4264-z